| Entry |
|
|---|
| Name |
Doravirine, lamivudine and tenofovir disoproxil;
Delstrigo (TN) |
|---|
| Product |
|
|---|
| Component |
Doravirine [DR: D10624], Lamivudine [DR: D00353], (Tenofovir disoproxil fumarate [DR: D01982] | Tenofovir disoproxil phosphate [DR: D10834] | Tenofovir disoproxil maleate [DR: D11391])
|
|---|
| Class |
Antiviral
DG03107 Anti-HIV agent
Metabolizing enzyme substrate
DG01633 CYP3A/CYP3A4 substrate
|
|---|
| Remark |
|
|---|
| Efficacy |
Antiviral |
|---|
| Disease |
|
|---|
| Comment |
Doravirine is metabolized by CYP3A.
|
|---|
| Target |
HIV-1 reverse transcriptase [KO: K24802] |
|---|
| Pathway |
|
|---|
| Metabolism |
|
|---|
| Interaction |
|
|---|
| Brite |
Anatomical Therapeutic Chemical (ATC) classification [BR:br08303]
J ANTIINFECTIVES FOR SYSTEMIC USE
J05 ANTIVIRALS FOR SYSTEMIC USE
J05A DIRECT ACTING ANTIVIRALS
J05AR Antivirals for treatment of HIV infections, combinations
J05AR24 Lamivudine, tenofovir disoproxil and doravirine
D11396 Doravirine, lamivudine and tenofovir disoproxil <US>
USP drug classification [BR:br08302]
Antivirals
Anti-HIV Combinations
Doravirine/ Lamivudine/ Tenofovir Disoproxil Fumarate
D11396 Doravirine, lamivudine and tenofovir disoproxil
Drug groups [BR:br08330]
Antiviral
DG03107 Anti-HIV agent
D11396 Doravirine, lamivudine and tenofovir disoproxil
Metabolizing enzyme substrate
DG01633 CYP3A/CYP3A4 substrate
D11396 Doravirine, lamivudine and tenofovir disoproxil
Drug classes [BR:br08332]
Antiviral
DG03107 Anti-HIV agent
D11396 Doravirine, lamivudine and tenofovir disoproxil
Antimicrobials [BR:br08307]
Antivirals
Genome replication inhibitor
HIV reverse transcriptase inhibitor
D11396 Doravirine, lamivudine and tenofovir disoproxil <US>
Drug metabolizing enzymes and transporters [br08309.html]
Drug metabolizing enzymes
D11396
|
|---|
| Other DBs |
|
|---|
| LinkDB |
|
|---|
